Prognostic Markers of Post-Stroke Depression (PROMoSD)
- Conditions
- Acute Ischemic Stroke
- Interventions
- Diagnostic Test: Transcranial sonography.
- Registration Number
- NCT05580198
- Lead Sponsor
- Ruhr University of Bochum
- Brief Summary
Single-center prospective observational study investigating the association of brainstem raphe hypoechogenicity detected by transcranial sonography and post-stroke depression three months after an acute ischemic stroke.
- Detailed Description
Post-stroke depression (PSD) is an important complication after a stroke. Despite significant limitations between studies of PSD risk factors, stroke severity or post-stroke disability, prior depressive episodes, and female sex are arguably the most well-known risk factors for developing PSD, although the predictive value of these factors is limited.
A hypoechogenic brainstem raphe (BR) detected by transcranial sonography (TCS) is associated with depressive symptoms in distinct diseases but is also common with approximately 25% of the non-depressed population in Europe. The primary aim of this study is to investigate the association between BR hypoechogenicity and PSD occurrence in a prospective observational study design.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 105
- Acute ischemic stroke with the onset of symptoms within the past 14 days
- Diagnosis of AIS is confirmed by brain imaging, either computer tomography or magnetic resonance imaging
- Insufficient transtemporal bone window for transcranial sonography examination
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description BRH+ Transcranial sonography. Acute ischemic stroke patients with brainstem raphe hypoechogenicity. BRH- Transcranial sonography. Acute ischemic stroke patients without brainstem raphe hypoechogenicity.
- Primary Outcome Measures
Name Time Method Post-stroke depression 3 months PSD diagnosis was defined according to the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V criteria) or by any new medication for anti-depressive indication during follow-up
- Secondary Outcome Measures
Name Time Method Severity of depressive symptoms 3 months Measured by the Hamilton Depression Rating Scale (HRSD, minimum score: 0, maximum score: 52), with higher scores indicating greater severity of depressive symptoms.
Trial Locations
- Locations (1)
St. Josef-Hospital Bochum
🇩🇪Bochum, Nordrhein-Westfalen, Germany